Dapagliflozin in the therapy of chronic heart failure of functional class II–III with moderately reduced ejection fraction

DOI: https://doi.org/10.29296/25877305-2023-12-06
Issue: 
12
Year: 
2023

N. Zaporozhskaya; E. Kartashova, Candidate of Medical Sciences; E. Zheleznyak, Candidate of Medical Sciences
Rostov State Medical University, Ministry of Health of Russia

The authors discuss the treatment of chronic heart failure (CHF) and present the results of our own study on the use of dapagliflozin in combination with standard therapy in patients with CHF. The comparison group consisted of patients receiving standard therapy with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-adrenoblockers and mineralocorticoid receptor antagonists.
Keywords: 
ardiology
chronic heart failure
moderately reduced ejection fraction
II–III functional class
dapagliflozin.

References: 
  1. Kramer C.K., Zinman B. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes. Annu Rev Med. 2019; 70: 323–34. DOI: 10.1146/annurev-med-042017-094221.
  2. Wiviott S.D., Raz I., Bonaca M.P. et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018; 200: 83–9. DOI: 10.1016/j.ahj.2018.01.012
  3. McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381 (21): 1995–2008. DOI: 10.1056/NEJMoa1911303
  4. Dewan P., Jackson A., Lam C.S.P. et al. Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. Eur J Heart Fail. 2020; 22 (5): 898–901. DOI: 10.1002/ejhf.1776
  5. Solomon S.D., Vaduganathan M., Claggett B.L. et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020; 141 (5): 352–61. DOI: 10.1161/CIRCULATIONAHA.119.044586